Skip to main content
SpringerLink
Log in

Idiosyncratic Drug-Induced Haematological Abnormalities

Incidence, Pathogenesis, Management and Avoidance

  • Review Article
  • Pharmacoepidemiology
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Haematological dyscrasias remain important because they are potentially fatal. Their accurate reporting is required to confirm the cause-effect relationship of suspected adverse drug reactions (ADRs); to estimate their incidence; and, by risk-benefit analysis of such events, to introduce preventive measures to reduce their impact. Limitations within the available data on haematological ADRs are reviewed and some suggestions made for improvement. The drugs most commonly associated with haematological dyscrasias are listed. An understanding of the pathogenesis of haematological dyscrasias is essential for their effective management and these are briefly reviewed. Features common to the management of the different types of haematological dyscrasia include the early involvement of a haematologist and drug information pharmacist and the accurate identification and early withdrawal of any likely offending agent. Guidelines for the management of drug-induced aplastic anaemia, agranulocytosis, thrombocytopenia and haemolytic anaemia are presented and the potential value of granulocyte and granulocyte-macrophage colony-stimulating factors (G-CSF; GM-CSF) in the management of agranulocytosis is specifically mentioned. Finally, general principles are discussed whereby serious haematological ADRs might be prevented. These include: the importance of continuing education for drug prescribers; policies on the restricted prescribing of likely offending agents; the use of written instructions for patients; and, the use of haematological monitoring. The guidelines presented in this article should be adapted to meet local circumstances and would prove suitable subjects for audit of their effectiveness.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Steel K, Gertman PM, Crescenzi C, et al. Iatrogenic illness on a general medical service at a university hospital. N Engl J Med 1981; 304: 638–42

    PubMed  CAS  Google Scholar 

  2. Lakshmanan ML, Hershey CO, Breslau D. Hospital admissions caused by iatrogenic disease. Arch Intern Med 1986; 146: 1931–4

    PubMed  CAS  Google Scholar 

  3. Faich GA. Adverse-drug-reaction monitoring. N Engl J Med 1986; 314: 1589–92

    PubMed  CAS  Google Scholar 

  4. Bottiger LE, Furhoff AK, Holberg L. Fatal reactions due to drugs. A study of 10 years material from the Swedish Adverse Drug Reaction Committee. Acta Med Scand 1979; 205: 457–61

    PubMed  CAS  Google Scholar 

  5. Young GAR. Drug-induced haematological disorders. Curr Ther 1984; 25: 61–9

    Google Scholar 

  6. Vincent PC. Drug-induced aplastic anaemia and agranulocytosis. Drugs 1986; 31: 52–63

    PubMed  CAS  Google Scholar 

  7. Heimpel H. Drug-induced agranulocytosis. Med Toxicol 1988; 3: 449–62

    CAS  Google Scholar 

  8. Dukes MNG. The importance of adverse reactions in drug regulation. Drug Saf 1990; 5: 3–6

    PubMed  CAS  Google Scholar 

  9. Arneborn P, Palmblad J. Drug-induced neutropenia: a survey for Stockholm 1973-–978. Acta Med Scand 1982; 212: 289–92

    PubMed  CAS  Google Scholar 

  10. Keith MR, Bellanger-McCleery RA, Fuchs JE. Multidisciplinary program for detecting and evaluating adverse drug reactions. Am J Hosp Pharm 1989; 46: 1809–12

    PubMed  CAS  Google Scholar 

  11. Kramer MS, Leventhal JM, Hutchinson TA, et al. An algorithm for the operational assessment of adverse drug reactions. JAMA 1979; 242: 623–32

    PubMed  CAS  Google Scholar 

  12. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–45

    PubMed  CAS  Google Scholar 

  13. Kaufman DK, Kelly JP, Levy M, et al. The drug etiology of agranulocytosis and aplastic anaemia. Monographs in epidemiology and biostatistics. No 18. New York: Oxford University Press, 1991

    Google Scholar 

  14. Edwards IR, Lindquist M, Wiholm B-E, et al. Quality criteria for early signals of possible adverse drug reactions. Lancet 1990; 336: 156–8

    PubMed  CAS  Google Scholar 

  15. Patton WN, Holyoake TL, Yates JM, et al. Accelerated recovery from drug-induced agranulocytosis following G-CSF therapy. Br J Haematol 1992; 80: 564–5

    PubMed  CAS  Google Scholar 

  16. Schlesselman JJ. Case control studies: design, conduct, analysis. Monographs in epidemiology and biostatistics. No 2. New York: Oxford University Press, 1982

    Google Scholar 

  17. Kramer MS, Lane DA, Hutchinson TA. Analgesic use, blood dyscrasias and case control pharmacoepidemiology: a critique of the International Agranulocytosis and Aplastic Anaemia Study. J Chron Dis 1987; 40: 1073–81

    PubMed  CAS  Google Scholar 

  18. International Agranulocytosis and Aplastic Anaemia Study (IAAAS). The design of a study of the drug etiology of agranulocytosis and aplastic anaemia. Eur J Clin Pharmacol 1983; 24: 833–6

    Google Scholar 

  19. The International Agranulocytosis and Aplastic Anemia Study. Risks of agranulocytosis and aplastic anaemia: a first report of their relation to drug use with special reference to analgesics. JAMA 1986; 256: 1749–57

    Google Scholar 

  20. International Agranulocytosis and Aplastic Anaemia Study. Risk of agranulocytosis and aplastic anaemia in relation to use of antithyroid drugs. BMJ 1988; 297: 262–5

    Google Scholar 

  21. A report from the International Agranulocytosis and Aplastic Anemia Study. Anti-infective drug use in relation to the risk of agranulocytosis and aplastic anemia. Arch Intern Med 1989; 149: 1036–40

    Google Scholar 

  22. Kelly JP, Kaufman DW, Shapiro S. Risks of agranulocytosis and aplastic anemia in relation to the use of cardiovascular drugs. Clin Pharmacol Ther 1991; 49: 330–41

    PubMed  CAS  Google Scholar 

  23. Committee on Safety of Medicines. Neutropenia and agranulocytosis with Carbimazole — may be fatal if the drug is not withdrawn promptly. Curr Probl 1991; 32: 2

    Google Scholar 

  24. Bottiger LE, Westerholm B. Drug-induced blood dyscrasias in Sweden. BMJ 1973; 3: 339–43

    PubMed  CAS  Google Scholar 

  25. Arneborn P, Palmblad J. Drug-induced neutropenia in the Stockholm region 1971–1975: frequency and causes. Acta Med Scand 1978; 204: 283–6

    PubMed  CAS  Google Scholar 

  26. Arneborn P, Palmblad J. Drug-induced neutropenias in the Stockholm region 1976–1977. Acta Med Scand 1979; 206: 241–3

    PubMed  CAS  Google Scholar 

  27. Palva IP, Mustala OO. Drug-induced agranulocytosis II. The role of medication in a fatal outcome. I Adults. Acta Med Scand 1972; 191: 121–4

    PubMed  CAS  Google Scholar 

  28. Inman MHW. Study of fatal bone marrow depression with special reference to phenylbutazone and oxyphenbutazone. BMJ 1977; 6: 1500–5

    Google Scholar 

  29. Pisciotta AV, Ebbe S, Lennon EJ, et al. Agranulocytosis following administration of phenothiazine derivatives. Am J Med 1958; 25: 210–23

    PubMed  CAS  Google Scholar 

  30. Pretty HM, Gosselin G, Colpron G, et al. Agranulocytosis: a report of 30 cases. Can Med Assoc J 1965; 93: 1058–64

    PubMed  CAS  Google Scholar 

  31. Julia A, Olona M, Bueno J, et al. Drug-induced agranulocytosis: prognostic factors in a series of 168 episodes. Br J Haematol 1991; 79: 366–71

    PubMed  CAS  Google Scholar 

  32. Mary JY, Baumelou E, Guiget M, et al. Epidemiology of aplastic anaemia in France: a prospective multicentre study. Blood 1990; 75: 1646–53

    PubMed  CAS  Google Scholar 

  33. Issaragrisil S, Sriratanasatavorn C, Piankijagum A, et al. Incidence of aplastic anaemia in Bangkok. The Aplastic Anaemia Study Group. Blood 1991; 77: 2166–8

    PubMed  CAS  Google Scholar 

  34. Szklo M, Sensenbrenner L, Markowitz J, et al. Incidence of aplastic anemia in metropolitan Baltimore: a population-based study. Blood 1985; 66: 115–9

    PubMed  CAS  Google Scholar 

  35. Linet MS, McCaffrey LD, Morgan WF, et al. Incidence of aplastic anemia in a three county area in South Carolina. Cancer Res 1986; 46: 426–9

    PubMed  CAS  Google Scholar 

  36. Clausen N. A population study of severe aplastic anemia in children: incidence, etiology and course. Acta Paediatr Scand 1986; 75: 58–63

    PubMed  CAS  Google Scholar 

  37. Davies SM, Walker DJ. Aplastic anaemia in the northern region 1971–1978 and follow-up of long term survivors. Clin Lab Haematol 1986; 8: 307–13

    PubMed  CAS  Google Scholar 

  38. Cartwright RA, McKinney PA, Williams L, et al. Aplastic anaemia incidence in parts of the United Kingdom in 1985. Leuk Res 1988; 12: 459–63

    PubMed  CAS  Google Scholar 

  39. Aggio MC, Alverez RV, Bartomioli MA, et al. Incidence and etiology of aplastic anemia in a defined population of Argentina (1966–1977). Medicina (B Aires) 1988; 48: 231–3

    CAS  Google Scholar 

  40. Irvine AE, French A, Daly A, et al. Drug-induced neutropenia due to direct effects on CFU-C: ten years of culture experience. Eur J Haematol 1994; 52: 21–7

    PubMed  CAS  Google Scholar 

  41. Pisciotta AV. Drug-induced agranulocytosis. Peripheral destruction of polymorphonuclear leukocytes and their marrow precursors. Blood Rev 1990; 4: 226–37

    PubMed  CAS  Google Scholar 

  42. Stroncek DF. Drug-induced immune neutropenia. Transfus Med Rev 1993; 7: 268–74

    PubMed  CAS  Google Scholar 

  43. McFarland JG. Laboratory investigation of drug-induced immune thrombocytopenias. Transfus Med Rev 1993; 7: 275–87

    PubMed  CAS  Google Scholar 

  44. Garratty G, Petz LD. Drug-induced immune hemolytic anemia. Am J Med 1975; 58: 398–407

    PubMed  CAS  Google Scholar 

  45. Williams DM. Pancytopenia, aplastic anaemia and pure red cell aplasia. In: Lee GR, Bithell TC, Foerster J, et al., editors. Wintrobe’s clinical haematology. Philadelphia: Lea and Febiger, 1993: 911–43

    Google Scholar 

  46. Champlin RE. Aplastic anaemia. In: Bick RL, editor. Hematology, clinical and laboratory practice. St Louis: Mosby, 1993: 471–94

    Google Scholar 

  47. Athens JW. Neutropenia. In: Lee GR, Bithell TC, Foerster J, et al., editors. Wintrobe’s clinical haematology. Philadelphia: Lea and Febiger, 1993: 1589–612

    Google Scholar 

  48. Foerster J. Autoimmune hemolytic anaemias. In: Lee GR, Bithell TC, Foerster J, et al., editors. Wintrobe’s clinical haematology. Philadelphia: Lea and Febiger, 1993: 1170–96

    Google Scholar 

  49. Lee RG. Acquired hemolytic anaemias resulting from direct effects of infectious, chemical or physical agents. In: Lee GR, Bithell TC, Foerster J, et al., editors. Wintrobe’s clinical haematology. Philadelphia: Lea and Febiger, 1993: 1197–210

    Google Scholar 

  50. Bithell TC. Thrombocytopenia caused by immunological platelet destruction: idiopathic thrombocytopenic purpura (ITP), drug-induced thrombocytopenia and miscellaneous forms. In: Lee GR, Bithell TC, Foerster J, et al., editors. Wintrobe’s clinical haematology. Philadelphia: Lea and Febiger, 1993: 1329–55

    Google Scholar 

  51. Bick RL. Quantitative platelet defects. In: Bick RL, editor. Hematology, clinical and laboratory practice. St Louis: Mosby, 1993: 1337–68

    Google Scholar 

  52. Chong BH. Drug-induced immune thrombocytopenia. Platelets 1991; 2: 173–81

    PubMed  CAS  Google Scholar 

  53. Committee on Safety of Medicines. Drug-induced neutropenia and agranulocytosis. Curr Probl 1993; 19: 10–1

    Google Scholar 

  54. Baum CM, Uchida N, Peault B, et al. Isolation and characterization of hematopoietic progenitor and stem cells. In: Forman ST, Blume KG, Thomas ED, editors. Bone marrow transplantation. Boston: Blackwell Scientific Publications, 1994: 53–71

    Google Scholar 

  55. Gordon MY. Human haematopoietic stem cell assays. Blood Rev 1993; 7: 190–7

    PubMed  CAS  Google Scholar 

  56. Clark SC, Kamen R. The human hematopoietic colony-stimulating factors. Science 1987; 236: 1229–37

    PubMed  CAS  Google Scholar 

  57. Nathan DG. Regulation of hematopoiesis. Pediatr Res 1990; 27: 423–43

    PubMed  CAS  Google Scholar 

  58. Lekhakula A, Swasdikul D. Drug-induced agranulocytosis: experience in two university hospitals. J Med Assoc Thai 1991; 74: 121–30

    PubMed  CAS  Google Scholar 

  59. Treleaven T, Barrett J. Drugs and the bone marrow. Br J Hosp Med 1990; 44: 245–50

    PubMed  CAS  Google Scholar 

  60. Ruvidic R, Jelic S. Haematological aspects of drug-induced agranulocytosis. Scand J Haematol 1972; 9: 18–27

    PubMed  CAS  Google Scholar 

  61. Muroi K, Ito K, Sasaki R, et al. Treatment of drug-induced agranulocytosis with granulocyte colony-stimulating factor. Lancet 1989; 2: 55

    PubMed  CAS  Google Scholar 

  62. Heinrich B, Gross M, Goebel FD. Methimazole-induced agranulocytosis and granulocyte colony-stimulating factor. Ann Intern Med 1989; 111: 621–2

    PubMed  CAS  Google Scholar 

  63. Delannoy A, Gehenot M. Colony-stimulating factor and drug-induced agranulocytosis. Ann Intern Med 1989; 110: 942–3

    PubMed  CAS  Google Scholar 

  64. Sonada Y, Yashige H, Fujii H, et al. Treatment of idiopathic neutropenia in the elderly with recombinant human granulocyte colony-stimulating factor. Acta Haematol 1991; 85: 146–52

    Google Scholar 

  65. Nand S, Bayer R, Prinz RA, et al. Granulocyte-macrophage colony stimulating factor for the treatment of drug induced agranulocytosis. Am J Hematol 1991; 37: 267–9

    PubMed  CAS  Google Scholar 

  66. Weide R, Koppler H, Heymanns J, et al. Successful treatment of clozapine-induced agranulocytosis with granulocyte-col-ony stimulating factor. Br J Haematol 1992; 80: 557–9

    PubMed  CAS  Google Scholar 

  67. Yokoyama K, Sato T, Nakijima S, et al. Successful treatment of methimazole-induced agranulocytosis by granulocyte colony-stimulating factor. Am J Hematol 1992; 40: 76–7

    PubMed  CAS  Google Scholar 

  68. Delannoy A. GM-CSF therapy for drug induced agranulocytosis. J Intern Med 1992; 231: 269–71

    PubMed  CAS  Google Scholar 

  69. Kendra JR, Rugman FP, Flaherty TA, et al. First use of G-CSF in chlorpromazine-induced agranulocytosis: a report of two cases. Postgrad Med J 1993; 69: 885–7

    PubMed  CAS  Google Scholar 

  70. Patton WN, Bradford CR, Cappellari G, et al. Use of colony stimulating factors for the treatment of drug-induced agranulocytosis [letter]. Br J Haematol 1993; 182–5

    Google Scholar 

  71. Mani S, Barry M, Concato J. Granulocyte-colony stimulating factor therapy in drug-induced agranulocytosis. Arch Intern Med 1993; 153: 2500–1

    PubMed  CAS  Google Scholar 

  72. Kurzrock R, Talpaz M, Gutterman JU. Very low doses of GMCSF administered alone or with erythropoietin in aplastic anaemia. Am J Med 1992; 93: 41–8

    PubMed  CAS  Google Scholar 

  73. Petz LD. Drug-induced autoimmune hemolytic anemia. Transfus Med Rev 1993; 7: 242–54

    PubMed  CAS  Google Scholar 

  74. Shulman NR, Jordan JV. Platelet immunology. In: Colman RW, Hirsh J, Marder VJ, et al., editors. Hemostasis and thrombosis. 2nd ed. Philadelphia: Lippincott, 1987: 452–529

    Google Scholar 

  75. Deren B, Masi R, Weksler M, et al. Gold-associated thrombocytopenia. Arch Intern Med 1974; 134: 1012–5

    PubMed  CAS  Google Scholar 

  76. Coblyn JS, Weinblatt M, Holdsworth D, et al. Gold-induced thrombocytopenia. A clinical and immunogenetic study of twenty-three patients. Ann Intern Med 1981; 95: 178–81

    PubMed  CAS  Google Scholar 

  77. Pisciotta AV, Kaidahl J. Studies on agranulocytosis IV. Effects of chlorpromazine on nucleic acid synthesis of bone marrow cells in vitro. Blood 1962; 20: 364–76

    PubMed  CAS  Google Scholar 

  78. Pisciotta AV, Pawlowski N, Peterson L, et al. Studies on agranulocytosis IX. A biochemical defect in chlorpromazine sensitive marrow cells. J Lab Clin Med 1971; 78: 435–48

    PubMed  CAS  Google Scholar 

  79. Breckenridge A. Adverse effects of ACE inhibitors and the quality of life. In: MacGregor GA, Sever PS, editors. Current advances in ACE inhibition. Proceedings of an International Symposium on ACE inhibition, Feb 14–17 1989, London. Edinburgh: Churchill Livingstone, 1989: 123–7

    Google Scholar 

  80. Cooper RA. Captopril-associated neutropenia. Arch Intern Med 1983; 143: 659–60

    PubMed  CAS  Google Scholar 

  81. Irvin JD, Viau JM. Safety profiles of the angiotensin-converting enzyme inhibitors Captopril and enalapril. Am J Med 1986; 81 Suppl. 4C: 46–50

    PubMed  CAS  Google Scholar 

  82. Bianco R. Adverse reactions with ACE inhibitors. New Ethicals 1986; 23: 181–208

    Google Scholar 

  83. Neftel KA, Hauser SP, Muller MR. Inhibition of granulopoiesis in vivo and in vitro by beta-lactam antibiotics. J Infect Dis 1985; 152: 90–8

    PubMed  CAS  Google Scholar 

  84. Singh N, Yu VL, Mieles LA, et al. β-Lactam antibiotic-induced leukopenia in severe hepatic dysfunction: risk factors and implications for dosing in patients with liver disease. Am J Med 1993; 94: 251–6

    PubMed  CAS  Google Scholar 

  85. Ross MP, Allen-Webb EM, Pappas JB, et al. Amrinone-associ-ated thrombocytopenia: pharmacokinetic analysis. Clin Pharmacol Ther 1993; 53: 661–7

    PubMed  CAS  Google Scholar 

  86. Cunningham JL, Leyland MJ, Delamore IW, et al. Acetanilide oxidation in phenylbutazone-associated hypoplastic anaemia. BMJ 1974; 3: 313–7

    PubMed  CAS  Google Scholar 

  87. Gerson SL, Arce C, Meitzer HY. N-desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis. Br J Haematol 1994; 86: 555–61

    PubMed  CAS  Google Scholar 

  88. Gerson SL, Lieberman JA, Friedenberg WR, et al. Polypharmacy in fatal clozapine-associated agranulocytosis. Lancet 1991; 338: 262

    PubMed  CAS  Google Scholar 

  89. Gordon-Smith EC. Drug-induced oxidative haemolysis. Clin Haematol 1980; 9: 557–85

    PubMed  CAS  Google Scholar 

  90. British Medical Association and Royal Pharmaceutical Society of Great Britain. Antiprotozoal drugs: primaquine. In: Prasad AB, editor. British National Formulary No. 26. London: Pharmaceutical Press, 1993: 239

    Google Scholar 

  91. Uetrecht J. Mechanism of hypersensitivity reactions: proposed involvement of reactive metabolites generated by activated leukocytes. Trends Pharmacol Sci 1989; 10: 463–7

    PubMed  CAS  Google Scholar 

  92. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukaemia. Ann Intern Med 1966; 64: 328–40

    PubMed  CAS  Google Scholar 

  93. Dale DC. Neutrophil disorders: benign quantitative abnormalities of neutrophils; neutropenia. In: Williams WJ, Beutler E, Erslev AJ, et al., editors. Haematology. 4th ed. New York: McGraw Hill, 1990: 807–16

    Google Scholar 

  94. Crawford J, Ozer H, Johnson D, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. New Engl J Med 1991; 325: 164–70

    PubMed  CAS  Google Scholar 

  95. Nemunaitis J. Granulocyte-macrophage-colony stimulating factor: a review from preclinical development to clinical application. Transfusion 1993; 33: 70–83

    Google Scholar 

  96. Camitta BM, Storb R, Thomas ED. Aplastic anaemia. Pathogenesis, diagnosis, treatment and prognosis. N Engl J Med 1982; 306: 645–52, 712–8

    PubMed  CAS  Google Scholar 

  97. Kay AGL. Myelotoxicity of gold. BMJ 1976; 1: 1266–8

    PubMed  CAS  Google Scholar 

  98. Patton WN, Murray JA, Blake DR, et al. How should we monitor gold therapy? Lancet 1988; 1: 581–2

    PubMed  CAS  Google Scholar 

  99. Bower JS. Aplastic anaemia due to gold therapy unsuccessfully treated with BAL. N C Med J 1952; 13: 340

    PubMed  CAS  Google Scholar 

  100. Gluckman E, Horowitz MH, Champlin RE, et al. Bone marrow transplantation for severe aplastic anaemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood 1992; 79: 269–75

    PubMed  CAS  Google Scholar 

  101. Storb R. Bone marrow transplantation for aplastic anemia. In: Forman SJ, Blume KG, Thomas ED, editors. Bone marrow transplantation. Boston: Blackwell Scientific, 1994: 583–94

    Google Scholar 

  102. French Co-operative Group for the Study of Aplastic and Refractory Anaemias. Androgen therapy in aplastic anaemia: a comparative study of high and low doses of 4 different androgens. Scand J Haematol 1986; 36: 346–52

    Google Scholar 

  103. Najean Y. Androgen therapy of aplastic anaemia in a prospective study of 352 cases. Scand J Haematol 1979; 22: 342–56

    Google Scholar 

  104. Bacigalupo A, Chaple M, Hows J, et al. Treatment of aplastic anaemia (AA) with antilymphocyte globulin (ALG) and methylprednisolone (MPred) with or without androgens: a randomized trial from the EBMT SAA working party. Br J Haematol 1993; 83: 145–51

    PubMed  CAS  Google Scholar 

  105. Doney K, Storb R, Buckner CD, et al. Treatment of gold-induced aplastic anemia with immunosuppressive therapy. Br J Haematol 1988; 68: 469–72

    PubMed  CAS  Google Scholar 

  106. Hansen RM, Csuka ME, McCarty DJ, et al. Gold-induced aplastic anaemia: complete response to corticosteroids, plasma pheresis and N-acetylcysteine infusion. J Rheumatol 1985; 12: 794–7

    PubMed  CAS  Google Scholar 

  107. Ray JB, Brereton WF, Nullet FR. Intravenous immune globulin for the treatment of presumed quinidine-induced thrombocytopenia. Ann Pharmacother 1990; 24: 693–5

    CAS  Google Scholar 

  108. Freiman JP. Fatal quinine-induced thrombocytopenia. Ann Intern Med 1990; 112: 308–9

    PubMed  CAS  Google Scholar 

  109. Spearing RL, Hickton CM, Sizeland P, et al. Quinine-induced disseminated intravascular coagulation. Lancet 1990; 336: 1535–7

    PubMed  CAS  Google Scholar 

  110. Gottschall JL, Elliot W, Lianos E, et al. Quinine-induced immune thrombocytopenia associated with hemolytic uremic syndrome: a new clinical entity. Blood 1991; 77: 306–10

    PubMed  CAS  Google Scholar 

  111. Gruel Y, Lang M, Darnige L, et al. Fatal effect of re-exposure to heparin after previous heparin-associated thrombocytopenia and thrombosis. Lancet 1990; 336: 1077–8

    PubMed  CAS  Google Scholar 

  112. King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med 1984; 100: 535–40

    PubMed  CAS  Google Scholar 

  113. Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Annu Rev Med 1989; 40: 31–44

    PubMed  CAS  Google Scholar 

  114. Laster JL, Nichols WK, Silver D. Thrombocytopenia associated with heparin-coated catheters in patients with heparin associated antibodies. Arch Intern Med 1989; 149: 2285–7

    PubMed  CAS  Google Scholar 

  115. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 1986; 67: 27–30

    PubMed  CAS  Google Scholar 

  116. Warkentin TE, Hayward CPM, Smith CM, et al. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med 1992; 120: 371–9

    PubMed  CAS  Google Scholar 

  117. Keeling DM, Richards EM, Baglin TP. Platelet aggregation in response to four low molecular weight heparins and the heparinoid Org (10172) in patients with heparin-induced thrombocytopenia. Br J Haematol 1994; 86: 425–6

    PubMed  CAS  Google Scholar 

  118. Chong BH, Ismail F, Cade J, et al. Heparin induced thrombocytopenia: studies with a low molecular weight heparinoid, Org 10172. Blood 1989; 73: 1592–6

    PubMed  CAS  Google Scholar 

  119. Ortel TL, Gockerman JP, Califf RM, et al. Parenteral anticoagulation with the heparinoid Lomoparin (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. Thromb Hemost 1992; 67: 292–6

    CAS  Google Scholar 

  120. Demers C, Ginsberg JS, Brill-Edwards P, et al. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood 1991; 78: 2194–7

    PubMed  CAS  Google Scholar 

  121. Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Prog Hemost Thromb 1991; 10: 1–34

    PubMed  CAS  Google Scholar 

  122. Worlledge SM. Immune drug-induced hemolytic anaemias. Semin Hematol 1969; 6: 181–200

    PubMed  CAS  Google Scholar 

  123. Garratty G, Postoway N, Schwellenbach J, et al. A fatal case of ceftriaxone (Rocephin)-induced hemolytic anaemia associated with intravascular immune hemolysis. Transfusion 1991; 31: 176–9

    PubMed  CAS  Google Scholar 

  124. Garratty G, Nance S, Lloyd M, et al. Fatal immune hemolytic anaemia due to cefotetan. Transfusion 1992; 32: 269–71

    PubMed  CAS  Google Scholar 

  125. Johnson FP, Hamilton HE, Liesch MR. Immune hemolytic anaemia associated with sulindac. Arch Intern Med 1985; 145: 1515–6

    PubMed  Google Scholar 

  126. Tofani O, Mazzoli M, Landini G, et al. Fatal acute immune haemolytic anaemia caused by nalidixic acid. BMJ 1982; 285: 936–7

    Google Scholar 

  127. Idanpaan-Heikkila J, Alhava E, Olkinura M. Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 1977; 11: 193–8

    PubMed  CAS  Google Scholar 

  128. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-in-duced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329: 162–7

    PubMed  CAS  Google Scholar 

  129. Walker ID, Walker JJ, Colvin BT, et al. Investigation and management of haemorrhagic disorders in pregnancy. J Clin Pathol 1994; 47: 100–8

    PubMed  CAS  Google Scholar 

  130. British Medical Association and Royal Pharmaceutical Society of Great Britain. Antibacterial drugs: chloramphenicol. In: Prasad AB, editor. British National Formulary No. 26. London: Pharmaceutical Press, 1993: 219

    Google Scholar 

  131. British Medical Association and Royal Pharmaceutical Society of Great Britain. Non-steroidal anti-inflammatory drugs (NSAID’s): indomethacin. In: Prasad AB, editor. British National Formulatary No 26. London: Pharmaceutical Press, 1993: 353, 356

    Google Scholar 

  132. Hirsch SR, Puri BK. Clozapine: progress in treating refractory schizophrenia [editorial]. BMJ 1993; 306: 1427–8

    PubMed  CAS  Google Scholar 

  133. Clozaril Patient Monitoring Service. Sandoz Pharmaceuticals, Frimley, Camberley, Surrey, UK

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Christchurch Hospital, Christchurch, New Zealand

    W. Nigel Patton

  2. Department of Clinical Pharmacology, Christchurch Hospital, Christchurch, New Zealand

    Stephen B. Duffull

Authors
  1. W. Nigel Patton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen B. Duffull
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Patton, W.N., Duffull, S.B. Idiosyncratic Drug-Induced Haematological Abnormalities. Drug-Safety 11, 445–462 (1994). https://doi.org/10.2165/00002018-199411060-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199411060-00006

Keywords

Search

Navigation